IP Library Patent Application 17346106
Patent Application
App. No. 17/346,106

CANCER DIAGNOSTICS USING BIOMARKERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/346,106
Abstract

Disclosed herein, in certain instances, are methods, systems and kits for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods, systems and kits for determining the treatment modality of a cancer in a subject. The methods, systems and kits comprise expression-based analysis of biomarkers. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject.

Claims (38)

1 . A method of diagnosing, prognosing, determining progression the cancer, or predicting benefit from therapy in a subject, comprising:

(a) assaying an expression level in a sample from the subject for a plurality of targets, wherein the plurality of targets comprises one or more targets selected from Tables 2, 4, 11 or 55; and

(b) diagnosing, prognosing, determining progression the cancer, or predicting benefit from therapy in a subject based on the expression levels of the plurality of targets.

2 . A method of determining a treatment for a cancer in a subject, comprising:

(a) assaying an expression level in a sample from the subject for a plurality of targets, wherein the plurality of targets comprises one or more targets selected from Tables 2, 4, 11 or 55; and

(b) determining the treatment for the cancer based on the expression level of the plurality of targets.

3 . The method of claim 1 , wherein the cancer is selected from the group consisting of a carcinoma, sarcoma, leukemia, lymphoma, myeloma, and a CNS tumor.

4 . The method of claim 1 , wherein the cancer is selected from the group consisting of skin cancer, lung cancer, colon cancer, pancreatic cancer, prostate cancer, liver cancer, thyroid cancer, ovarian cancer, uterine cancer, breast cancer, cervical cancer, kidney cancer, epithelial carcinoma, squamous carcinoma, basal cell carcinoma, melanoma, papilloma, and adenomas.

5 - 26 . (canceled)

27 . A probe set for assessing a cancer status of a subject comprising a plurality of probes, wherein the probes in the set are capable of detecting an expression level of one or more targets selected from Tables 2, 4, 11 or 55, wherein the expression level determines the cancer status of the subject with at least 40% specificity.

28 - 32 . (canceled)

33 . The probe set of claim 27 , wherein the probe set further comprises a probe capable of detecting an expression level of at least one coding target.

34 . The probe set of claim 33 , wherein the coding target is an exonic sequence.

35 . The probe set of claim 27 , wherein the probe set further comprises a probe capable of detecting an expression level of at least one non-coding target.

36 . The probe set of claim 35 , wherein the non-coding target is an intronic sequence or partially overlaps with an intronic sequence.

37 . The probe set of claim 35 , wherein the non-coding target is a UTR sequence or partially overlaps with a UTR sequence.

38 - 40 . (canceled)

41 . The probe set of claim 27 , wherein the target is a nucleic acid sequence.

42 . The probe set of claim 41 , wherein the nucleic acid sequence is a DNA sequence.

43 . The probe set of claim 41 , wherein the nucleic acid sequence is an RNA sequence.

44 - 59 . (canceled)

60 . The probe set of claim 27 , wherein the non-coding target is a non-coding RNA transcript and the non-coding RNA transcript is non-polyadenylated.

61 . A system for analyzing a cancer, comprising:

(a) a probe set comprising a plurality of target sequences, wherein

(i) the plurality of target sequences hybridizes to one or more targets selected from Tables 2 or 4; or

(ii) the plurality of target sequences comprises one or more target sequences selected from Table 11; and

(b) a computer model or algorithm for analyzing an expression level and/or expression profile of the target hybridized to the probe in a sample from a subject suffering from a cancer.

62 . The system of claim 61 , further comprising an electronic memory for capturing and storing an expression profile.

63 . The system of claim 61 , further comprising a computer-processing device, optionally connected to a computer network.

64 - 78 . (canceled)

79 . A method of analyzing a cancer in an individual in need thereof, comprising:

(a) obtaining an expression profile from a sample obtained from the individual, wherein the expression profile comprises one or more targets selected from Tables 2, 4, 11 or 55; and

(b) comparing the expression profile from the sample to an expression profile of a control or standard.

80 - 173 . (canceled)

174 . A kit for analyzing a cancer, comprising:

(a) a probe set comprising a plurality of target sequences, wherein the plurality of target sequences comprises at least one target sequence listed in Table 11; and

(b) a computer model or algorithm for analyzing an expression level and/or expression profile of the target sequences in a sample.

175 - 184 . (canceled)

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2023
From: BUERKI, CHRISTINE; CRISAN, ANAMARIA; DAVICIONI, ELAI; ERHO, NICHOLAS GEORGE; GHADESSI, MERCEDEH; VERGARA CORREA, ISMAEL A.
To: GENOMEDX BIOSCIENCES, INC.
Reel/Frame 065636/0583 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2023
From: JENKINS, ROBERT B.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 065636/0652 →
CHANGE OF NAME Recorded Nov 21, 2023
From: GENOMEDX BIOSCIENCES INC.
To: GENOMEDX INC.
Reel/Frame 065658/0737 →
CHANGE OF NAME Recorded Nov 21, 2023
From: GENOMEDX INC.
To: DECIPHER BIOSCIENCES, INC.
Reel/Frame 065659/0230 →
CHANGE OF NAME Recorded Nov 21, 2023
From: DECIPHER BIOSCIENCES, INC.
To: VERACYTE SD, INC.
Reel/Frame 065659/0780 →